Funding round will support development of lead targeted alpha therapy ADVC001 in metastatic prostate cancer and expand Lead-212 manufacturing capabilities.

Acquisition gives Lilly late-stage psychedelic pipeline targeting treatment-resistant depression and major psychiatric disorders

Acquisition adds FDA-authorised fibromyalgia therapy and strengthens smartphone-based digital health offering

The agreement expands AstraZeneca’s oncology portfolio with an oral EGFR inhibitor for non-small-cell lung cancer, as Dizal seeks to broaden Zegfrovy’s use into earlier lines of treatment.

Neuropsychiatric drug developer Draig Therapeutics has raised $65 million in an oversubscribed Series B financing round to accelerate development of its pipeline, led by its investigational depression therapy DT-101.

The latest agreement strengthens the companies’ collaboration as they target a major central nervous system indication using AI-powered drug discovery.

The deal gives Bayer additional financial flexibility while allowing the company to retain operational control of its long-acting reversible contraceptives portfolio.

The agreement gives AstraZeneca exclusive rights to develop, manufacture and commercialise TQC3721 outside China.

The new funding will accelerate manufacturing and commercial deployment of the FDA-cleared Marie system, which reimagines proton therapy by rotating the patient instead of the treatment machine.

The deal gives Vertex access to a commercial acromegaly therapy and a late-stage rare disease pipeline as the company diversifies beyond cystic fibrosis.

The agreement adds advanced imaging capabilities to the xvision Spine System platform, supporting broader adoption of augmented reality navigation in spinal procedures.

The acquisition adds functional electrical stimulation technology to Ottobock’s neuro-orthotics offering, strengthening its position in the growing neurological devices market.

The collaboration will evaluate Vivani’s implantable semaglutide technology as Novo Nordisk looks to expand treatment options beyond once-weekly injections.

The clinical-stage biotech plans to use a potential public listing to accelerate development of melanocortin-based therapies targeting obesity and cancer cachexia.

The agreement with Sino Biopharmaceutical gives AstraZeneca ex-China rights to TQC3721, an experimental dual PDE3/4 inhibitor being developed for chronic respiratory diseases.

New funding will support a pivotal Phase III trial comparing deupirfenidone head-to-head with Roche’s Esbriet as competition intensifies in idiopathic pulmonary fibrosis.

Genentech has secured global rights to a fragment-based drug discovery programme targeting a key regulator of breast cancer cell growth.

The acquisition adds a novel antibody-drug conjugate payload platform and two preclinical oncology programmes targeting hard-to-treat solid tumours.

The in vivo gene editing biotech has announced IPO plans as it pushes its lead PCSK9 programme into first-in-human trials.

Funding will support the global SURPASS-IPF trial comparing deupirfenidone directly against standard-of-care pirfenidone in idiopathic pulmonary fibrosis.